26
Participants
Start Date
May 31, 2010
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
insulin degludec/insulin aspart
Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
Novo Nordisk Clinical Trial Call Center, Chula Vista
Lead Sponsor
Novo Nordisk A/S
INDUSTRY